Hyunseok Kang, MD | UniHealth

Offices

3 locations · Stanford Health Care · UCSF Medical Group Business Services · Regents of the University of California

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

10 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kang’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

10 of 10 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence C156305 · Current

Licensed to practise in California · since 2018 · expires 2027-10-31 · Yonsei University College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at UCSF Medical Center

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	4.9 (3.79 to 6.02) · 7,590 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	12.8 (11.3 to 14.4) · 2,019 cases	Worse	Jan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	139.4 (110.22 to 168.58) · 452 cases	Better	Jul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.622	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.626	Better	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.491	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.8 (0.7 to 1) · 2,336 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.24 (0.58 to 1.9) · 4,689 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	1.05 (0.89 to 1.2)	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.9 · 89 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.5 · 85 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 132 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.6 · 454 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 618 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	9.6 · 380 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.7 · 5,000 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.22 (0.06 to 0.38) · 15,965 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.2 (0.05 to 0.35) · 17,859 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.85 (0 to 1.83) · 4,184 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2 (1.1 to 2.9) · 6,516 cases	No different	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	7.35 (4.49 to 10.21) · 3,989 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5 (3.22 to 6.77) · 4,087 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.95 (0.74 to 3.15) · 2,034 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.95 (0.63 to 1.28) · 15,431 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	4 · 399 cases	None	Apr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.899	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.689	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	1.224	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16 · 156 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20 · 564 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	60.3 · 160 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-9.7 · 550 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	44.1 · 660 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.8 · 667 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.7 (4.8 to 6.7) · 2,019 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	6 · 421 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	10.5 · 53 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	20 · 107 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	13.9 (11.3 to 17.1) · 3,247 cases	No different	Jan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at UCSF Medical Center

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at UCSF Medical Center

Room was "always" clean	71%
Nurses "always" communicated well	80%
Doctors "always" communicated well	80%
Staff "always" explained	61%
Yes, staff "did" give patients this information	88%
Yes, staff "did" give patients information about help after discharge	87%
Doctors "always" explained things so they could understand	74%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	86%
Patients who gave a rating of "9" or "10" (high)	76%
Staff "always" explained new medications	75%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	78%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	50%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	46%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$53,989

Medicare paid this office $53,989 for 135 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	91	$29,789	$124
New patient visit (60+ min)	47	$7,251	$154
Return visit (30+ min)	50	$5,516	$74

Who their Medicare patients are

135 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 10% · Women 35% · Also on Medicaid 32% · Health risk score 2.39. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 62% · Cancer 25% · Depression 24% · Chronic kidney disease 22% · Coronary heart disease 21% · Diabetes 19% · COPD 18% · Atrial fibrillation 16% · Heart failure 9% · Dementia 8%.

The office billed $355,735, Medicare allowed $71,001 and paid $53,989; for 598 services of 13 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	135	598	72	2.39	$355,735	$53,989
2023	128	1,191	72	2.23	$470,922	$74,850
2022	135	397	72	2.38	$277,006	$41,632
2021	115	355	72	2.14	$268,786	$43,169
2020	92	321	73	2.55	$239,236	$31,178
2019	109	343	72	2.40	$280,678	$35,182
2018	117	273	72	2.21	$125,167	$22,870
2017	144	318	70	2.20	$98,073	$33,300
2016	191	412	70	2.12	$121,780	$40,006
2015	174	407	69	1.95	$122,473	$43,209
2014	128	424	68	2.00	$117,420	$42,238
2013	41	69	69	1.88	$21,722	$7,892

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	90	$17,058	$80
Long return visit (40+ min)	53	$14,013	$126
New patient visit (60+ min)	53	$8,236	$155

2022: 3 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	83	$16,239	$83
Long return visit (40+ min)	53	$12,342	$122
New patient visit (60+ min)	63	$9,538	$151

2021: 3 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	65	$21,604	$129
New patient visit (60+ min)	64	$10,320	$161
Return visit (30+ min)	49	$9,174	$89

2020: 3 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	60	$18,580	$97
New patient visit (60+ min)	40	$5,922	$148
Return visit (30+ min)	29	$3,978	$71

2019: 3 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	64	$23,547	$97
New patient visit (60+ min)	67	$9,282	$139
Return visit (30+ min)	14	$1,223	$58

2018: 3 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	46	$8,208	$93
New patient visit (60+ min)	36	$5,172	$144
Return visit (30+ min)	53	$4,292	$60

2017: 5 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	62	$14,459	$107
Return visit (30+ min)	49	$5,374	$80
New patient visit (60+ min)	31	$5,264	$170
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$2,361	$87
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,209	$170

2016: 9 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	53	$9,824	$105
New patient visit (60+ min)	34	$5,763	$169
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	18	$4,666	$86
Long return visit (40+ min)	30	$4,526	$92
Return visit (30+ min)	45	$3,994	$80
New patient visit (60+ min)	20	$2,820	$141
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	11	$2,331	$57
Return visit (30+ min)	24	$1,562	$62
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	14	$1,520	$109

2015: 6 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	69	$14,957	$113
New patient visit (60+ min)	44	$7,331	$167
Return visit (30+ min)	51	$7,291	$81
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	24	$4,772	$87
Initial hospital care with moderate level of medical decision making at least 75 minutes	21	$3,561	$170
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	19	$2,287	$114

2014: 7 services

Sort by

Original Medicare services billed in 2014

Return visit (30+ min)	61	$12,773	$87
Long return visit (40+ min)	37	$9,192	$116
New patient visit (60+ min)	43	$7,159	$166
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	19	$5,069	$86
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	18	$2,061	$115
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	20	$1,551	$60
Hospital discharge day management, 30 minutes or less	12	$722	$60

2013: 3 services

Sort by

Original Medicare services billed in 2013

Long return visit (40+ min)	14	$2,865	$119
Return visit (30+ min)	19	$2,592	$89
New patient visit (60+ min)	12	$1,886	$157

Medicaid work

$22,721 in 2024

Medicaid paid $22,721 for 172 billed services this clinician did in 2024, up to 18 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Long return visit (40+ min)	172	$22,721

Sort by

Medicaid work by year

2024	172	1	18	$22,721
2023	110	2	14	$10,964
2022	203	2	19	$18,130
2021	211	4	16	$10,723
2020	38	2	14	$2,145
2019	17	1	13	$1,068

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Return visit (30+ min)	74	$6,370
Long return visit (40+ min)	36	$4,594

2022

Sort by

Largest Medicaid services in 2022

Return visit (30+ min)	158	$13,514
Long return visit (40+ min)	45	$4,615

2021

Sort by

Largest Medicaid services in 2021

Return visit (30+ min)	112	$9,358
COMPREHENSIVE METABOLIC PANEL	43	$608
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	41	$425
Thyroid stimulating hormone (TSH)	15	$332

2020

Sort by

Largest Medicaid services in 2020

Long return visit (40+ min)	17	$1,887
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	21	$258

2019

Sort by

Largest Medicaid services in 2019

Long return visit (40+ min)	17	$1,068

Drugs they prescribed that Part D paid

$1,336,215

Pharmacies billed $1,336,215 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

128 generic and 81 brand-name prescriptions · $1,336,215 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Lenvima	19	$436,205	$22,958
Mekinist	20	$256,477	$12,824
Tafinlar	15	$171,302	$11,420
Retevmo	12	$169,313	$14,109
Ondansetron	37	$637	$17

See all 7 drugs

Sort by

Every Part D drug this clinician prescribed

Lenvima	19	$436,205	$22,958
Mekinist	20	$256,477	$12,824
Tafinlar	15	$171,302	$11,420
Retevmo	12	$169,313	$14,109
Ondansetron	37	$637	$17
Dexamethasone	12	$320	$27
Prochlorperazine Maleate	28	$250	$9

Year by year

Sort by

Part D prescribing by year

2024	209	58	None	39%	$1,336,215
2023	262	68	None	25%	$1,158,020
2022	206	64	None	None	$608,160
2021	192	48	None	21%	$416,861
2020	194	39	None	20%	$143,002
2019	191	34	None	29%	$262,960
2018	144	31	None	34%	$27,306
2017	131	33	None	27%	$18,736
2016	100	35	None	17%	$2,688
2015	76	22	25% (19)	16%	$5,002
2014	133	27	None	18%	$24,529
2013	119	35	13% (15)	18%	$11,270

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 7 drugs

Sort by

Part D drugs prescribed in 2023

Lenvima	13	$299,582	$23,045
Tafinlar	20	$253,120	$12,656
Retevmo	11	$219,187	$19,926
Mekinist	12	$158,287	$13,191
Ondansetron	54	$636	$12
Dexamethasone	24	$579	$24
Prochlorperazine Maleate	42	$576	$14

2022: 5 drugs

Sort by

Part D drugs prescribed in 2022

Tafinlar	15	$161,707	$10,780
Mekinist	11	$129,232	$11,748
Ondansetron	42	$832	$20
Prochlorperazine Maleate	44	$592	$13
Dexamethasone	16	$533	$33

2021: 4 drugs

Sort by

Part D drugs prescribed in 2021

Bicalutamide	13	$603	$46
Ondansetron	34	$578	$17
Dexamethasone	18	$462	$26
Prochlorperazine Maleate	40	$429	$11

2020: 6 drugs

Sort by

Part D drugs prescribed in 2020

Dexamethasone	21	$491	$23
Ondansetron	23	$301	$13
Prochlorperazine Maleate	27	$290	$11
Bicalutamide	13	$279	$21
Potassium Chloride	12	$179	$15
Amlodipine Besylate	14	$28	$2

2019: 6 drugs

Sort by

Part D drugs prescribed in 2019

Mekinist	11	$124,360	$11,305
Dexamethasone	21	$644	$31
Ondansetron	29	$326	$11
Levothyroxine	14	$152	$11
Prochlorperazine Maleate	19	$138	$7
Lisinopril	13	$106	$8

2018: 5 drugs

Sort by

Part D drugs prescribed in 2018

Xarelto	12	$5,836	$486
Levothyroxine	50	$645	$13
Prochlorperazine Maleate	26	$376	$14
Ondansetron	11	$293	$27
Dexamethasone	12	$218	$18

2017: 3 drugs

Sort by

Part D drugs prescribed in 2017

Prochlorperazine Maleate	23	$617	$27
Levothyroxine	43	$539	$13
Dexamethasone	11	$197	$18

2016: 2 drugs

Sort by

Part D drugs prescribed in 2016

Levothyroxine	26	$373	$14
Prochlorperazine Maleate	14	$234	$17

2014: 3 drugs

Sort by

Part D drugs prescribed in 2014

Enoxaparin	19	$19,735	$1,039
Ondansetron	11	$306	$28
Dexamethasone	11	$70	$6

2013: 1 drug

Sort by

Part D drugs prescribed in 2013

Ondansetron	12	$788	$66

Money from drug and device companies

$4,294 in 2024

Sort by

Industry payments by year

2024	3	5	$3,950	$4,294
2023	4	9	$2,748	$10,083
2022	4	5	$17,673	$17,793
2021	3	3	$4,380	$4,392
2020	6	8	$4,638	$5,124
2019	6	24	$10,032	$13,803

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Coherus Biosciences	Loqtorzi	$3,962	3 payments Paid to speak or teach for Loqtorzi · 2024-06-01 · $3,750 Meals for Udenyca · 2024-06-01 · $148 Meals · 2024-02-12 · $64
Genzyme	Caprelsa	$200	1 payment Paid to speak or teach for Caprelsa · 2024-03-12 · $200
Regeneron Healthcare Solutions	Libtayo	$132	1 payment Meals for Libtayo · 2024-06-20 · $132

See all 5 published payments

Sort by

Every published payment

Regeneron Healthcare Solutions	Meals · 2024-06-20	Libtayo	$132
Coherus Biosciences	Paid to speak or teach · 2024-06-01	Loqtorzi	$3,750
Coherus Biosciences	Meals · 2024-06-01	Udenyca	$148
Genzyme	Paid to speak or teach · 2024-03-12	Caprelsa	$200
Coherus Biosciences	Meals · 2024-02-12	None	$64

See earlier years (2023, 2022, 2021, 2020, 2019)

2023: $10,083

Sort by

Payments by company in 2023

Eli Lilly and	None	$7,304	6 payments Travel · 2023-10-23 · $142 Travel · 2023-10-23 · $5,728 Travel · 2023-10-23 · $54 Travel · 2023-10-23 · $103 Travel · 2023-10-23 · $1,102 Travel · 2023-10-23 · $175
Bayer Healthcare Pharmaceuticals	Vitrakvi	$1,428	1 payment Consulting for Vitrakvi · 2023-01-25 · $1,428
Exelixis	Cabometyx	$1,320	1 payment Paid to speak or teach for Cabometyx · 2023-09-28 · $1,320
Illumina	Oncology Testing	$31	1 payment Meals for Oncology Testing · 2023-11-15 · $31

2022: $17,793

Sort by

Payments by company in 2022

Bayer HealthCare Pharmaceuticals	Vitrakvi	$11,420	1 payment Consulting for Vitrakvi · 2022-05-17 · $11,420
Coherus Biosciences	None	$3,495	2 payments Meals · 2022-08-15 · $120 Consulting · 2022-06-03 · $3,375
Exelixis	Cabometyx	$2,640	1 payment Paid to speak or teach for Cabometyx · 2022-11-11 · $2,640
AstraZeneca Pharmaceuticals LP	None	$238	1 payment Paid to speak or teach · 2022-09-07 · $238

2021: $4,392

Sort by

Payments by company in 2021

Coherus Biosciences	None	$2,400	1 payment Honoraria · 2021-12-01 · $2,400
Exelixis	Cabometyx	$1,980	1 payment Paid to speak or teach for Cabometyx · 2021-04-14 · $1,980
Gilead Sciences	None	$12	1 payment Education · 2021-06-01 · $12

2020: $5,124

Sort by

Payments by company in 2020

GlaxoSmithKline	None	$3,083	2 payments Consulting · 2020-01-20 · $2,925 Travel · 2020-01-20 · $158
Bayer HealthCare Pharmaceuticals	Vitrakvi	$1,713	1 payment Consulting for Vitrakvi · 2020-12-02 · $1,713
Eli Lilly and	None	$154	2 payments Meals · 2020-02-03 · $82 Travel · 2020-02-03 · $72
Pfizer	None	$74	1 payment Meals · 2020-02-13 · $74
Puma Biotechnology	Nerlynx	$60	1 payment Meals for Nerlynx · 2020-02-15 · $60
Pharmacyclics LLC An AbbVie	Imbruvica	$40	1 payment Meals for Imbruvica · 2020-02-14 · $40

2019: $13,803

Sort by

Payments by company in 2019

Bayer HealthCare Pharmaceuticals	Vitrakvi	$7,738	9 payments Meals for Vitrakvi · 2019-05-01 · $10 Travel for Vitrakvi · 2019-05-01 · $29 Consulting for Vitrakvi · 2019-05-01 · $6,900 Travel for Vitrakvi · 2019-05-01 · $22 Meals for Vitrakvi · 2019-05-01 · $124 Travel for Vitrakvi · 2019-05-01 · $321 Travel for Vitrakvi · 2019-05-01 · $23 Travel for Vitrakvi · 2019-05-01 · $28 Travel for Vitrakvi · 2019-03-28 · $281
F. Hoffmann-La Roche AG	Perjeta	$3,132	2 payments Paid to speak or teach for Perjeta · 2019-06-30 · $353 Paid to speak or teach for Perjeta · 2019-03-31 · $2,779
Exelixis	None	$2,698	9 payments Travel · 2019-04-12 · $142 Meals · 2019-04-12 · $61 Meals · 2019-04-12 · $30 Meals · 2019-04-12 · $30 Travel · 2019-04-12 · $56 Travel · 2019-04-11 · $1,788 Travel · 2019-04-11 · $142 Travel · 2019-04-11 · $324 Meals · 2019-04-11 · $127
Genentech USA	Avastin	$212	2 payments Meals for Avastin · 2019-09-28 · $85 Meals for Avastin · 2019-06-01 · $127
GlaxoSmithKline	None	$19	1 payment Meals · 2019-09-27 · $19
Genentech	Tecentriq	$4	1 payment Meals for Tecentriq · 2019-06-14 · $4

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2021	Their institution	$472,314
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2022	Their institution	$347,836
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors Including Ret Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With Ret Activation (Libretto-001) · 2023	Their institution	$262,160
Merck Sharp & Dohme Corporation · A Phase II, Open-Label, Multi-Center Trial of Pds0101 Immunomapk-Rdotap,Hpv-16 E6 & E7 Peptides and Pembrolizumab in Patients With Recurrent Or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 Hpv16 Infection After Failure With Platinum-Based Chemotherapy · 2021	Their institution	$248,471
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-260 in Patients With Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation Refractory To Selective Ret Inhibitors · 2024	Their institution	$87,828
Merck Sharp & Dohme LLC · A Phase II, Open-Label, Multi-Center Trial of Pds0101 Immunomapk-Rdotap,Hpv-16 E6 & E7 Peptides and Pembrolizumab in Patients With Recurrent Or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 Hpv16 Infection After Failure With Platinum-Based Chemotherapy · 2022	Their institution	$79,698
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2024	Their institution	$37,736
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-260 in Patients With Ret Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With Ret Activation Refractory To Selective Ret Inhibitors · 2023	Their institution	$35,804
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2025	Their institution	$28,985
Eli Lilly and Company · A Multicenter, Randomized, Open Label, Phase 3 Trial Comparing Selpercatinib To Physicians Choice of Cabozantinib Or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naive, Ret Mutant Medullary Thyroid Cancer (Libretto 531) · 2021	Their institution	$19,854
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2019	Their institution	$16,891
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (Xl184) in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2022	Their institution	$10,245
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-260 in Patients With Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation Refractory To Selective Ret Inhibitors · 2025	Their institution	$5,907
Exelixis Inc. · A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib Xl184 in Subjects With Radioiodine Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy · 2021	Their institution	$2,660

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 75.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1316108509
Licence: CA C156305, MD D76615California C156305: Current · expires 2027-10-31
Group: Stanford Health Care · UCSF Medical Group Business Services · Regents of the University of California
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2008-06-19
NPI last updated: 2025-12-08
NPI record certified: 2025-12-08

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur Dr, Palo Alto, CA, 94304